NLS Pharmaceutics Secures $1 Million in Final Equity Financing
In a significant development for NLS Pharmaceutics Ltd., the company has successfully closed its second and final round of equity financing, raising $1 million as part of a larger $3 million initiative. This financing will support the company's merger with Kadimastem and enhance its portfolio of therapies.
Details of the Financing Round
The latest closing involved the issuance of 606,061 preferred shares at a conversion price of $1.65 per share, which reflects a 10% premium over the market price at the time the agreement was finalized. The first part of this financing was successfully completed earlier in the year, bringing the total gross proceeds to $3 million.
Strategic Use of Funds
The funds obtained from this equity financing are allocated for various initiatives, including supporting the pending merger with Kadimastem, a company pioneering advanced cell therapies. Additionally, these resources are intended to bolster working capital and general operations, providing a solid foundation for future growth.
Comments from Leadership
Alex Zwyer, the CEO of NLS, remarked that the completion of this financing round showcases investors' unwavering confidence in the company's strategic outlook and its collaborative efforts with Kadimastem. He is optimistic about leveraging these strengthened financial resources to finalize the merger and advance a diverse pipeline focused on central nervous system (CNS) disorders.
Kadimastem's Perspective
Ronen Twito, the Executive Chairman of Kadimastem, expressed his conviction in the added funding's role as a catalyst for their joint venture. This infusion of capital is expected to propel the company's Phase IIa clinical trials for AstroRx®, targeting amyotrophic lateral sclerosis (ALS), as well as Phase I studies for IsletRx, aimed at diabetes treatment.
Progress Towards Merger Completion
The closing of this financing series represents a continuation of the progression towards the merger between NLS Pharmaceutics and Kadimastem. This merger remains subject to the typical conditions, including the necessary regulatory and shareholder approvals.
About NLS Pharmaceutics
With a robust focus on next-generation therapies, NLS Pharmaceutics is dedicated to addressing sleep disorders, neurodegenerative diseases, and metabolic dysfunctions. The company is advancing innovative dual orexin receptor agonists through a strategic partnership with Aexon Labs, exemplifying its commitment to restoring sleep-wake balance and reducing neuroinflammation.
Insight into Kadimastem
Recognized for its leading role in cell therapies, Kadimastem specializes in developing allogeneic cell products. AstroRx®, their flagship product, is currently in clinical trials for ALS therapy, while IsletRx is designed to manage diabetes more effectively. Kadimastem was founded by Professor Michel Revel, an esteemed scientist whose innovations have greatly influenced the field of molecular genetics.
Frequently Asked Questions
What is the recent financing amount raised by NLS Pharmaceutics?
NLS Pharmaceutics recently raised $1 million in their second closing of a $3 million equity financing round.
What will the funds be used for?
The funds will primarily be used to support the merger with Kadimastem and to fund working capital and other corporate activities.
When was the initial closing of the financing?
The initial closing of this financing occurred earlier in the year, representing a $2 million round.
What is the role of Kadimastem?
Kadimastem focuses on developing cell therapies, particularly for ALS and diabetes, as part of its collaboration with NLS Pharmaceutics.
Who is the CEO of NLS Pharmaceutics?
The CEO of NLS Pharmaceutics is Alex Zwyer, who has emphasized the company’s growth strategy and funding success.
